Adnan Tufail

About Adnan Tufail

Adnan Tufail

Consultant Ophthalmologist, Moorfields Eye Hospital; Institute of Ophthalmology, UCL, London, UK

Adnan is the clinical and research lead for AMD at Moorfields, and he’s achieved a lot in that role. He was a co-principal investigator in the seminal ABC Trial that focused on examining bevacizumab for the treatment of neovascular AMD, which had a profound effect on eyecare in the UK: it defined anti-VEGF treatment protocols for wet-AMD therapy within the NHS. He’s also an early pioneer of big data and machine learning in ophthalmology, with numerous publications to his name on that topic to date. He founded an ARVO AI special interest group that grew into an all-day course, and is involved in the validation of machine learning algorithms that are being introduced into the UK for diabetic screening.

Adnan co-leads the €16 million Macustar Consortium, which unites industry and academia to drive dry AMD research, is the clinical lead of the largest-ever UK Medical Research Council grant to develop novel non-VEGF anti-angiogenic therapies, and he’s highly regarded in industry too. He’s initiated various important clinical trials in age-related macular degeneration, including some seminal big data real-world analyses that have revealed a lot of important information about clinical practice today. He is involved in laboratory as well as clinical research into treating a number of rare retinal diseases – and, on top of all that, he’s a gifted surgeon!

Going About Things In The Right Way